Document is current

Article History

Received: 5 March 2024

Accepted: 8 June 2024

First Online: 23 July 2024

Declarations

:

: This study was approved by the Ethics Committee of the Technical University of Munich, School of Medicine, University Hospital rechts der Isar, Munich, Germany (approval No. 2023-391-S-KK). It was conducted in accordance with the principles of the Declaration of Helsinki. Before participating in the survey, participants declared consent to the privacy policy and further use of anonymised data after completing the online survey. Written informed consent was not obtained from participants; instead, they received participant information and privacy policy and declared consent for the further use of anonymised data after completing the online survey.

: JS reports grants, personal fees, and non-financial support from AbbVie, Gilead Sciences, Janssen-Cilag, GSK/ViiV Healthcare, and MSD; Dr. Falk Pharma GmbH, Diasorin, Deutsche Forschungsgemeinschaft and the Central Innovation Programme for small- and medium-sized enterprises outside the submitted work. CDS reports grants, personal fees from AstraZeneca; personal fees and non-financial support from BBraun Melsungen; personal fees from BioNtech; grants, personal fees and non-financial support from Gilead Sciences; grants and personal fees from Janssen-Cilag; personal fees from Eli Lilly; personal fees from Formycon; personal fees from Pfizer; personal fees from Roche; other from Apeiron; grants and personal fees from MSD; grants from Cepheid; personal fees from GSK; personal fees from Molecular partners; personal fees from Pfizer; other from Eli Lilly; personal fees from SOBI during the conduct of the study; personal fees from AbbVie; personal fees from MSD; personal fees from Synairgen; personal fees from Shionogi; grants and personal fees from ViiV Healthcare, outside the submitted work. JE reports non-financial support from Gilead Sciences, ViiV Healthcare, and Pfizer. FV reports personal fees and non-financial support from Gilead Sciences and ViiV Healthcare, and grants from MSD and B. Braun Melsungen AG outside of the submitted work. CB reports personal honoraria for lectures and/or consultancies from AbbVie, Astra Zeneca, Bavarian Nordic, Gilead Sciences, Janssen Pharmaceuticals, MSD, Pfizer and ViiV Healthcare as well as institutional funding from Deutsche Leberstiftung, DZIF, Hector Stiftung and NEAT-ID.